Liu David Y 4

4 · Protagonist Therapeutics, Inc · Filed Nov 17, 2022

Form 4

Period: 2022-11-16

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2022-11-16$0.87/sh+13,767$11,977→ 80,878 total
Exercise/Conversion
Common Stock
2022-11-16$1.89/sh+5,999$11,338→ 96,603 total
Exercise/Conversion
Common Stock
2022-11-16$1.16/sh+35,656$41,361→ 132,259 total
Exercise/Conversion
Stock Option (right to buy)
2022-11-16−13,767→ 0 total
Exercise: $0.87Exp: 2023-09-26→ Common Stock (13,767 underlying)
Exercise/Conversion
Common Stock
2022-11-16$1.89/sh+9,726$18,382→ 90,604 total
Exercise/Conversion
Common Stock
2022-11-16$4.21/sh+35,331$148,744→ 167,590 total
Exercise/Conversion
Stock Option (right to buy)
2022-11-16−9,726→ 0 total
Exercise: $1.89Exp: 2024-10-22→ Common Stock (9,726 underlying)
Exercise/Conversion
Stock Option (right to buy)
2022-11-16−5,999→ 0 total
Exercise: $1.89Exp: 2025-03-26→ Common Stock (5,999 underlying)
Exercise/Conversion
Stock Option (right to buy)
2022-11-16−35,656→ 0 total
Exercise: $1.16Exp: 2025-10-28→ Common Stock (35,656 underlying)
Exercise/Conversion
Stock Option (right to buy)
2022-11-16−35,331→ 0 total
Exercise: $4.21Exp: 2026-04-29→ Common Stock (35,331 underlying)

Footnotes (2)

[F1]Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
[F2]The stock option is vested in full.

Documents

2 files